Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Core Insights - Junshi Biosciences announced promising long-term survival results for toripalimab from the JUPITER-02 and JUPITER-06 trials at the ESMO ASIA Congress 2025, highlighting its potential as a leading immunotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and advanced esophageal squamous cell carcinoma (ESCC) [1][2] Group 1: JUPITER-02 Trial - JUPITER-02 is the first global multicenter, double-blind, randomized Phase 3 trial in immunotherapy for NPC, demonstrating significant long-term survival benefits with toripalimab plus chemotherapy [3][6] - The trial enrolled 289 chemotherapy-naïve patients with R/M NPC, showing a median overall survival (mOS) of 64.8 months for the toripalimab group compared to 33.7 months for the placebo group, representing a 39% reduction in death risk [5][8] - Toripalimab plus chemotherapy is now approved in over 40 countries and endorsed by major international guidelines, establishing a new standard of care for first-line treatment of R/M NPC [6][8] Group 2: JUPITER-06 Trial - JUPITER-06 is a Phase 3 trial evaluating toripalimab combined with paclitaxel and cisplatin (TP) chemotherapy for advanced or metastatic ESCC, showing a mOS of 17.7 months compared to 12.9 months for the placebo group, with a 28% reduction in death risk [11][12] - The trial included 514 systemic treatment-naïve patients, confirming consistent overall survival benefits across subgroups, regardless of PD-L1 expression status [12][14] - Toripalimab has gained approval for first-line treatment of advanced ESCC in multiple regions, including Europe, marking a significant milestone in immunotherapy [14][19] Group 3: Company Overview - Junshi Biosciences is an innovation-driven biopharmaceutical company focused on developing novel therapies, with a diverse R&D pipeline of over 50 drug candidates across various therapeutic areas [20][21] - The company has successfully developed toripalimab, China's first domestically produced anti-PD-1 monoclonal antibody, which has been approved in over 40 countries [20][21] - Junshi Biosciences aims to provide world-class, affordable, and innovative drugs, with a commitment to global health [21]